Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 217

1.

Adherence to Nutrition and Physical Activity Cancer Prevention Guidelines and Development of Colorectal Adenoma.

Kohler LN, Harris RB, Oren E, Roe DJ, Lance P, Jacobs ET.

Nutrients. 2018 Aug 16;10(8). pii: E1098. doi: 10.3390/nu10081098.

2.

The role of bile acids in cellular invasiveness of gastric cancer.

Wu YC, Chiu CF, Hsueh CT, Hsueh CT.

Cancer Cell Int. 2018 May 21;18:75. doi: 10.1186/s12935-018-0569-0. eCollection 2018.

3.

Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth.

Kim EK, Cho JH, Kim E, Kim YJ.

PLoS One. 2017 Jul 14;12(7):e0181183. doi: 10.1371/journal.pone.0181183. eCollection 2017.

4.

Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence.

Bezzio C, Festa S, Saibeni S, Papi C.

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):339-347. doi: 10.1080/17474124.2017.1292129. Epub 2017 Feb 16. Review.

PMID:
28165825
5.

Greater Adherence to Cancer Prevention Guidelines Is Associated with Higher Circulating Concentrations of Vitamin D Metabolites in a Cross-Sectional Analysis of Pooled Participants from 2 Chemoprevention Trials.

Kohler LN, Hibler EA, Harris RB, Oren E, Roe DJ, Jurutka PW, Jacobs ET.

J Nutr. 2017 Mar;147(3):421-429. doi: 10.3945/jn.116.243352. Epub 2017 Jan 25.

6.

Chemoprevention of colorectal cancer in inflammatory bowel disease.

Ehrlich AC, Patel S, Meillier A, Rothstein RD, Friedenberg FK.

Expert Rev Anticancer Ther. 2017 Mar;17(3):247-255. doi: 10.1080/14737140.2017.1283987. Epub 2017 Feb 1. Review.

PMID:
28095263
7.

Risk and Surveillance of Cancers in Primary Biliary Tract Disease.

Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M, Imam M.

Gastroenterol Res Pract. 2016;2016:3432640. doi: 10.1155/2016/3432640. Epub 2016 Jun 19. Review.

8.

Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations.

Jacobs ET, Haussler MR, Alberts DS, Kohler LN, Lance P, Martínez ME, Roe DJ, Jurutka PW.

Cancer Prev Res (Phila). 2016 Jul;9(7):589-97. doi: 10.1158/1940-6207.CAPR-16-0033. Epub 2016 May 2.

9.

Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction.

Bessone F, Roma MG.

Ann Hepatol. 2016 May-Jun;15(3):442-7. doi: 10.5604/16652681.1198824.

10.

Primary rectal mucosa-associated lymphoid tissue lymphoma in a patient with previously identified primary biliary cirrhosis and secondary Sjögren's syndrome.

Kawashima K, Katakura K, Takahashi Y, Asama H, Fujiwara T, Kumakawa H, Ohira H.

Clin J Gastroenterol. 2016 Jun;9(3):124-8. doi: 10.1007/s12328-016-0643-x. Epub 2016 Apr 1.

11.

The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study.

Huang WK, Hsu HC, Liu JR, Yang TS, Chen JS, Chang JW, Lin YC, Yu KH, Kuo CF, See LC.

Medicine (Baltimore). 2016 Mar;95(11):e2980. doi: 10.1097/MD.0000000000002980.

12.

CANCERPREVENTIVE IN ULCERATIVE COLITIS.

Podolskaya DV, Shapina MV, Khalif IL.

Eksp Klin Gastroenterol. 2016;(8):4-8. Review. English, Russian.

PMID:
29874428
13.

Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.

Rossi RE, Conte D, Massironi S.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):123-31. doi: 10.1097/MEG.0000000000000532. Review.

PMID:
26636407
14.

[Differences between colorectal cancer patients and healthy people in fecal microbiota and metabolites].

Wang X, Wang J, Rao B, Deng L, Huang Y, Zeng G, Chen C.

Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Nov;18(11):1106-10. Chinese.

PMID:
26616803
15.

The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics.

Ridlon JM, Bajaj JS.

Acta Pharm Sin B. 2015 Mar;5(2):99-105. doi: 10.1016/j.apsb.2015.01.006. Epub 2015 Feb 9. Review.

16.

Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT).

Lozano E, Monte MJ, Briz O, Hernández-Hernández A, Banales JM, Marin JJ, Macias RI.

J Control Release. 2015 Oct 28;216:93-102. doi: 10.1016/j.jconrel.2015.08.022. Epub 2015 Aug 14.

PMID:
26278512
17.

Primary sclerosing cholangitis: a clinical update.

Williamson KD, Chapman RW.

Br Med Bull. 2015 Jun;114(1):53-64. doi: 10.1093/bmb/ldv019. Epub 2015 May 16. Review.

PMID:
25981516
18.

Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Fan CQ, Crawford JM.

J Clin Exp Hepatol. 2014 Dec;4(4):332-46. doi: 10.1016/j.jceh.2014.10.002. Epub 2014 Oct 30. Review.

19.

A novel function for UDP glycosyltransferase 8: galactosidation of bile acids.

Meech R, Mubarokah N, Shivasami A, Rogers A, Nair PC, Hu DG, McKinnon RA, Mackenzie PI.

Mol Pharmacol. 2015;87(3):442-50. doi: 10.1124/mol.114.093823. Epub 2014 Dec 17.

20.

Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.

Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J.

PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.

Supplemental Content

Loading ...
Support Center